8-Bromo-cAMP
8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA) . 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells[1][2].
Product Specifications
CAS Number
[23583-48-4]
Product Name Alternative
8-Br-Camp
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; PKA
Type
Reference compound
Related Pathways
Apoptosis; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/8-bromo-camp.html
Purity
99.48
Solubility
1 M NaOH : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OP1(O[C@@]2([H])[C@@H](O)[C@@H](O[C@]2([H])CO1)N3C(Br)=NC4=C3N=CN=C4N)=O
Molecular Formula
C10H11BrN5O6P
Molecular Weight
408.10
Precautions
H302, H315, H319, H335
References & Citations
[1]Wang Y, et al. A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev. 2011 Jun;7 (2) :331-41.|[2]Wang HM, et al. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol. 2005 Nov 7;11 (41) :6538-42.|[3]Baek MO, et al. Differential regulation of mTORC1 and mTORC2 is critical for 8-Br-cAMP-induced decidualization. Exp Mol Med. 2018 Oct 30;50 (10) :1-11. |[4]Wang S, et al. Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer. Onco Targets Ther. 2018 Jul 2;11:3765-3774
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Andrology. 2025 Jun 16.|Biochem Biophys Res Commun. 2025 Nov 19:790:152919.|Biochem Pharmacol. 2025 Jun 23:117060.|BMC Biol. 2024 May 3;22 (1) :104.|Chem Res Toxicol. 2025 Jul 21;38 (7) :1266-1280.|J Assist Reprod Genet. 2024 Nov;41 (11) :3189-3200.|J Mol Histol. 2025 Oct 22;56 (6) :348.|bioRxiv. 2025 March 25.|Cell Mol Life Sci. 2022 Nov 13;79 (12) :589.|Cell Oncol (Dordr) . 2023 Aug;46 (4) :953-967.|Cell Signal. 2024 Dec:124:111438.|Commun Biol. 2025 Jul 4;8 (1) :995.|EMBO J. 2024 Nov;43 (21) :5018-5036.|Environ Health (Wash) . 2024 Aug 16;2 (11) :776-785.|Hum Reprod. 2021 Jan 1;36 (1) :145-159.|Inflammation. 2022 Dec;45 (6) :2419-2432.|J Assist Reprod Genet. 2024 Jun;41 (6) :1645-1659.|J Bone Miner Metab. 2021 Sep;39 (5) :769-779.|J Hazard Mater. 2024 Jun 7:475:134854.|J Proteomics. 2025 Apr 3:316:105437.|Korean J Pain. 2023 Jul 1;36 (3) :335-346.|Mol Cell Endocrinol. 2023 Aug 20:574:111952.|Part Fibre Toxicol. 2022 Feb 17;19 (1) :13.|Reprod Biol Endocrinol. 2022 Sep 22;20 (1) :142.|Reprod Sci. 2023 Apr;30 (4) :1281-1290.|Res Sq. 2024 Sep 09.|Research Square Preprint. 2021 Jul|Research Square Preprint. 2021 Jul.|Sci Total Environ. 2022 Oct 10:842:156854.|SSRN. 2023 Aug 1.|Theriogenology. 2022 Sep 1:189:118-126.|University of Bonn. 2025.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
